MARKET

BOLT

BOLT

Bolt Biotherapeutics, Inc.
NASDAQ
0.3700
+0.0120
+3.35%
After Hours: 0.3610 -0.009 -2.43% 16:09 05/12 EDT
OPEN
0.3709
PREV CLOSE
0.3580
HIGH
0.3800
LOW
0.3521
VOLUME
48.40K
TURNOVER
--
52 WEEK HIGH
1.335
52 WEEK LOW
0.3000
MARKET CAP
14.19M
P/E (TTM)
-0.2238
1D
5D
1M
3M
1Y
5Y
1D
Bolt Biotherapeutics reports Q1 EPS (29c), consensus (36c)
TipRanks · 46m ago
*Bolt Biotherapeutics 1Q Rev $1.22M >BOLT
Dow Jones · 58m ago
Press Release: Bolt Biotherapeutics Reports First -2-
Dow Jones · 1h ago
*Bolt Biotherapeutics 1Q Loss/Shr 29c >BOLT
Dow Jones · 1h ago
Weekly Report: what happened at BOLT last week (0505-0509)?
Weekly Report · 12h ago
Biotech Alert: Searches spiking for these stocks today
TipRanks · 3d ago
Bolt Biotherapeutics Inc <BOLT.OQ> expected to post a loss of 36 cents a share - Earnings Preview
Reuters · 3d ago
Bolt Biotherapeutics to host KOL call on BDC-3042 Phase 1 results
TipRanks · 4d ago
More
About BOLT
More
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Recently
Symbol
Price
%Change

Webull offers Bolt Biotherapeutics Inc stock information, including NASDAQ: BOLT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BOLT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BOLT stock methods without spending real money on the virtual paper trading platform.